The effect of activation of angiogenesis pathways independent of VEGF in renal cell carcinoma on resistance to VEGF-targeted antiangiogenic therapy.

被引：0
|
作者：
Han, Kyung Seok [1 ]
Gust, Kilian [1 ]
Awrey, Shannon [1 ]
Raven, Peter A. [1 ]
Li, Estelle [1 ]
Fazli, Ladan [1 ]
Gleave, Martin E. [1 ]
So, Alan I. [1 ]
机构：
[1] Vancouver Prostate Ctr, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.409
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
409
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies
    Golshayan, Ali-Reza
    Brick, Ashley J.
    Choueiri, Toni K.
    FUTURE ONCOLOGY, 2008, 4 (01) : 85 - 92
  • [22] The impact of MET expression on patient outcomes with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT)
    Albiges, Laurence
    De Velasco, Guillermo
    Gray, Kathryn P.
    Carol, Hallie A.
    Caella, Marcella
    Mickey, Suzanne S.
    Fay, Andre P.
    Mcdermott, David F.
    Atkins, Michael B.
    Heng, Daniel Y.
    Signoretti, Sabina
    Choueiri, Toni K.
    BJU INTERNATIONAL, 2015, 116 : 1 - 2
  • [23] EVEROLIMUS IN METASTATIC RENAL CANCER CARCINOMA PROGRESSED ON VEGF-TARGETED THERAPY: A SINGLE-CENTRE EXPERIENCE
    Baldazzi, Valentina
    Tassi, Renato
    Lapini, Alberto
    Caruso, Salvatore
    Cipriani, Greta
    Diacciati, Sara
    Cerullo, Carmine
    Santomaggio, Carmine
    Carini, Marco
    Mazzanti, Roberto
    ANTICANCER RESEARCH, 2010, 30 (04) : 1473 - 1473
  • [24] Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma?
    Shepherd, Scott Thomas Colville
    Hall, Peter
    Brown, Janet Elizabeth
    Larkin, James M. G.
    Jones, Robert J.
    Ralph, Christy
    Hawkins, Robert E.
    Chowdhury, Simon
    Boleti, Ekaterini
    Bahl, Amit
    Fife, Kate
    Webb, Andrew
    Crabb, Simon J.
    Geldart, Thomas R.
    Dunlop, Joanna
    McLaren, Duncan
    Ackerman, Charlotte
    Beltran, Luis
    Nathan, Paul D.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
    Cho, Daniel C.
    ONCOTARGETS AND THERAPY, 2013, 6 : 679 - 684
  • [26] The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
    Sharpe, Kevin
    Stewart, Grant D.
    Mackay, Alan
    Van Neste, Christophe
    Rofe, Charlotte
    Berney, Dan
    Kayani, Irfan
    Bex, Axel
    Wan, Elaine
    O'Mahony, Fiach C.
    O'Donnell, Marie
    Chowdhury, Simon
    Doshi, Rukma
    Ho-Yen, Colan
    Gerlinger, Marco
    Baker, Dawn
    Smith, Neil
    Davies, Barry
    Sahdev, Anju
    Boleti, Ekaterini
    De Meyer, Tim
    Van Criekinge, Wim
    Beltran, Luis
    Lu, Yong-Jie
    Harrison, David J.
    Reynolds, Andrew R.
    Powles, Tom
    CLINICAL CANCER RESEARCH, 2013, 19 (24) : 6924 - 6934
  • [27] Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study
    Harshman, Lauren C.
    Xie, Wanling
    Bjarnason, Georg A.
    Knox, Jennifer J.
    MacKenzie, Mary
    Wood, Lori
    Srinivas, Sandy
    Vaishampayan, Ulka N.
    Tan, Min-Han
    Rha, Sun-Young
    Donskov, Frede
    Agarwal, Neeraj
    Kollmannsberger, Christian
    North, Scott
    Rini, Brian I.
    Heng, Daniel Y. C.
    Choueiri, Toni K.
    LANCET ONCOLOGY, 2012, 13 (09): : 927 - 935
  • [28] TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer
    Deng, Zhuo
    Zhou, Jiancheng
    Han, Xi
    Li, Xu
    ONCOLOGY REPORTS, 2016, 35 (01) : 359 - 365
  • [29] Gender as a factor associated with poor compliance in the treatment of metastatic renal cell carcinoma with VEGF-targeted therapy in Japanese patients.
    Uemura, Motohide
    Tsujimura, Akira
    Kawashima, Atsunari
    Arai, Yasuyuki
    Tanigawa, Go
    Nin, Mikio
    Yasunaga, Yutaka
    Yoshioka, Toshiaki
    Nomura, Hironori
    Mukai, Masatoshi
    Fukuda, Satoko
    Oka, Daizo
    Nishimura, Kenji
    Yoshida, Takahiro
    Satou, Mototaka
    Hatano, Koji
    Nakai, Yasutomo
    Takayama, Hitoshi
    Nishimura, Kazuo
    Nonomura, Norio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy
    Wood, L.
    Bukowski, R. M.
    Dreicer, R.
    Elson, P.
    Garcia, J. A.
    Gilligan, T.
    Mekhail, T.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345